Manchester and London, UK, 8 September, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has signed a research collaboration agreement under which C4XD's proprietary NMR-based technology will be applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.
C4XD has the only technology in the world that can generate accurate, experimentally-derived 3D structures of drug molecules in just a matter of days. It can be used in conjunction with existing technologies for structure-based design such as X-ray co-crystallography. Equally, it can also be used when crystallography is unavailable, as is the case for certain GPCRs and ion channels.
Piers Morgan, CEO of C4X, said "We are delighted to partner with Evotec, a global leader in high-quality drug discovery solutions. This collaboration will provide increased visibility of the potential advantages and benefits of C4XD's technology."
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased to partner with C4XD and are excited about the potential of this alliance. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."